Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome.
Xue Y, Religa P, Cao R, Hansen AJ, Lucchini F, Jones B, Wu Y, Zhu Z, Pytowski B, Liang Y, Zhong W, Vezzoni P, Rozell B, Cao Y.
Xue Y, et al. Among authors: cao r, cao y.
Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18513-8. doi: 10.1073/pnas.0807967105. Epub 2008 Nov 18.
Proc Natl Acad Sci U S A. 2008.
PMID: 19017793
Free PMC article.